دورية أكاديمية
A global investment case for hepatitis B elimination: a modelling study.
| العنوان: | A global investment case for hepatitis B elimination: a modelling study. |
|---|---|
| المؤلفون: | Seaman CP; Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Luong P; Burnet Institute, Melbourne, VIC, Australia., Xiao Y; Burnet Institute, Melbourne, VIC, Australia., Abeysuriya R; Burnet Institute, Melbourne, VIC, Australia., Howell J; Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, VIC, Australia., Hellard M; Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Doherty Institute and School of Population and Global Health, University of Melbourne, VIC, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia., Scott N; Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Electronic address: nick.scott@burnet.edu.au. |
| المصدر: | The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2023 Oct; Vol. 8 (10), pp. 932-942. Date of Electronic Publication: 2023 Jul 27. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Amsterdam] : Elsevier B.V., [2016]- |
| مواضيع طبية MeSH: | Health Care Costs* , Hepatitis B*/epidemiology , Hepatitis B*/prevention & control, Humans ; Models, Theoretical ; Cost-Benefit Analysis ; Cost of Illness |
| مستخلص: | Hepatitis B is estimated to cause 500 000-900 000 deaths globally each year. WHO has targets for elimination by 2030; however, progress has stalled due to multiple barriers, notably a paucity of global funding and insufficient evidence on the economic burden of disease. Using a dynamic mathematical model of hepatitis B transmission, disease progression, and mortality in the six WHO regions, we estimate the costs and benefits of reaching 90% vaccination, 90% diagnosis, and 80% treatment coverage by either 2030 (as targeted), 2040, or 2050. Without increased intervention coverage, hepatitis B mortality was estimated to cost US$784·35 billion (95% Crl 731·63-798·33 billion) globally in lost productivity over 2022-50. Achieving targets by 2030 averted 25·64 million infections (95% Crl 17·39-34·55 million) and 8·63 million hepatitis B-attributable deaths (95% Crl 7·12-9·74 million) over 2022-50. This achievement incurred an incremental cost of $2934·55 (95% Crl 2778·55-3173·52) per disability-adjusted life year averted by 2050 under a health systems perspective, and was cost-saving with a net economic benefit of $99·03 billion (95% Crl 78·66-108·96 billion) by 2050 from a societal perspective. Delayed achievement of intervention coverage targets had reduced health and economic benefits. These findings highlight that hepatitis B is an underappreciated cause of economic burden and show investment toward elimination will probably yield substantial returns. Competing Interests: Declaration of interests MH received investigator-initiated research grants from Gilead Science and AbbVie unrelated to this Health Policy. All other authors declare no competing interests. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20230730 Date Completed: 20230911 Latest Revision: 20231003 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/S2468-1253(23)00156-5 |
| PMID: | 37517417 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2468-1253 |
|---|---|
| DOI: | 10.1016/S2468-1253(23)00156-5 |